Abiopharma

Director STRYKER RONDA E 🟡 adjusted position in 0 shares (1 derivative) of STRYKER CORP (SYK) at $96.64 Transaction Date: Jan 14, 2026 | Filing ID: 000001

New Form 10-K - NovAccess Global Inc. Filed: 2026-01-14 AccNo: 0001185185-26-000158 Size: 6 MB

Leabman Michael Aaron 🔴 sold 12.3K shares of Movano Inc. (MOVE) at $7.01 Transaction Date: Jan 12, 2026 | Filing ID: 013106

(75% Positive) Absci Corporation (ABSI) Announces Enrollment Update for included Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Biomerica, Inc. - Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Notification from BriaCell Therapeutics Corp.

(99% Neutral) Emergent Biosolutions Inc. (EBS) Reports Q1 2026 Financial Results

Director Paterson Dan 🔴 sold 10.3K shares of Verastem, Inc. (VSTM) at $7.16 Transaction Date: Jan 12, 2026 | Filing ID: 003789

Aziz Kabeer 🟢 acquired 11.6K shares of AN2 Therapeutics, Inc. (ANTX) Transaction Date: Jan 12, 2026 | Filing ID: 013041

Martin Patricia A. 🟢 acquired 3.6K shares of AN2 Therapeutics, Inc. (ANTX) Transaction Date: Jan 12, 2026 | Filing ID: 013038

Marks Gilbert Lynn 🟢 acquired 11.6K shares of AN2 Therapeutics, Inc. (ANTX) Transaction Date: Jan 12, 2026 | Filing ID: 013035

New Form SCHEDULE 13G/A - FENNEC PHARMACEUTICALS INC. Filed: 2026-01-14 AccNo: 0001012975-26-000043 Size: 15 KB

Teva Pharmaceutical Industries Ltd. - AJOVY®(fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine